You are here

Angiochem Named as One of the “Fierce 15” Biotech Companies of


Angiochem Presents at the 2012 Barriers of the CNS Gordon Research Conference

Montreal, Canada, June 19, 2012 – Angiochem, a clinical stage biotechnology company, today announced that Jean Lachowicz Ph.D., Chief Scientific Officer of Angiochem will present at the 2012 Barriers of the CNS Gordon Research Conference, June 20, 2012 in New London, NH.

During her talk, entitled "Successfully Accessing the Brain using EPiC Technology,” Dr. Lachowicz will discuss how Angiochem’s EPiC technology has been applied to enable small molecules, peptides, and mAbs to cross the blood-brain barrier (BBB).  The resulting NCEs are promising therapeutics for treatment of a number of serious CNS diseases including brain cancer and pain.

About  EPiC Technology

Angiochem’s Engineered Peptide Compound (EPiC) Technology is the proven platform behind a new class of highly innovative and effective pharmaceuticals that address unmet medical needs involving brain diseases and CNS-related disorders. One of Angiochem's EPiC-derived drugs is in development for treatment of brain tumors and is achieving clinically meaningful outcomes.

Based on proprietary sequences of amino acids, called Angiopeps, which are engineered to specifically target the LRP-1 receptor, the EPiC technology platform is highly versatile and applicable to a range of therapeutic areas.


About Angiochem

Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough peptide drug conjugates that leverage the LRP-1 mediated pathway to cross the BBB to treat neurological diseases. These new EPiC compounds have the potential to address significant medical needs, many of which are insurmountable due to the fundamental physiological challenge posed by the BBB.


Angiochem is developing a focused product pipeline, including small molecules and biologics, for the potential treatment of a wide range of CNS diseases, including brain cancer, neurodegenerative and lysosomal storage diseases, pain, and others. Founded in 2003, Angiochem maintains headquarters in Montreal, Canada. For additional information about the Company, please visit


# # #


Media Contact:

Gina Nugent

The Yates Network



Business Development Contact:

Catherine Gagnon

Angiochem, Inc.

514-788-7800 x204